Post-bevacizumab Clinical Outcomes and the Impact of Early Discontinuation of Bevacizumab in Patients with Recurrent Malignant Glioma

PURPOSE: Bevacizumab±irinotecan is effective for treatment of recurrent malignant gliomas. However, the optimal duration of treatment has not been established. MATERIALS AND METHODS: Ninety-four consecutive patients with recurrent malignant glioma who were treated with bevacizumab at our institution...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Cancer Res Treat
Egile Nagusiak: Cha, Yongjun, Kim, Yu Jung, Lee, Se-Hoon, Kim, Tae-Min, Choi, Seung Hong, Kim, Dong-Wan, Park, Chul-Kee, Kim, Il Han, Kim, Jee Hyun, Kim, Eunhee, Choi, Byungse, Kim, Chae-Yong, Kim, In Ah, Heo, Dae Seog
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Korean Cancer Association 2017
Gaiak:
Original Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5266387/
https://ncbi.nlm.nih.gov/pubmed/27188199
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4143/crt.2015.466
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak